Neuland Laboratories Limited has issued a Letter of Confirmation in lieu of lost share certificates to a shareholder, as communicated to stock exchanges on March 19, 2026. The pharmaceutical company informed both BSE Limited and the National Stock Exchange of India about this regulatory compliance action.

Regulatory Compliance Details

The issuance was conducted pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI Circular No. SEBI/HO/MIRSD/MIRSD-RTAMB/P/CIR/2022/8 dated January 25, 2022. This regulatory framework governs the process for handling lost or misplaced share certificates and ensures proper documentation and disclosure to exchanges.

Share Certificate Details

The company approved the issuance of Letter of Confirmation for the following shareholder details:

Exchange Communication

The communication was addressed to both major Indian stock exchanges where Neuland Laboratories shares are listed. BSE Limited received the notification at Phiroze Jeejeebhoy Towers, while the National Stock Exchange of India was informed at their Exchange Plaza location in Bandra Kurla Complex. The company's scrip codes are 524558 on BSE and NEULANDLAB in the EQ series on NSE.

Corporate Governance

Company Secretary Sarada Bhamidipati signed the official communication on behalf of Neuland Laboratories Limited. The document was digitally signed on March 19, 2026, at 11:58:54 +05'30', demonstrating the company's commitment to digital documentation and regulatory compliance. This disclosure ensures transparency and maintains proper records for investor protection and regulatory oversight.

Neuland Laboratories has announced the sad demise of Dr. Christopher M Cimarusti, Non-Executive Non-Independent Director of the company. The pharmaceutical company informed stock exchanges that Dr. Cimarusti passed away on February 28, 2026.

Board Association and Contributions

Dr. Cimarusti had been associated with Neuland Laboratories' board since 2009, serving for over 17 years. During his tenure, the company benefited significantly from his vision, guidance, and valuable contributions, particularly in the research and development function. His long-standing association with the company reflects his commitment to its growth and development in the pharmaceutical sector.

Regulatory Compliance Details

The company has filed the mandatory disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was submitted to both BSE Limited and The National Stock Exchange of India Ltd on March 3, 2026.

Company Response

All directors and employees of Neuland Laboratories have expressed their deep sorrow and condolences to Dr. Cimarusti's family. The company acknowledged his significant contributions during his board tenure, emphasizing his impact on the organization's research and development capabilities.

The disclosure follows the requirements under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, ensuring compliance with regulatory obligations for changes in board composition.